• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4: Silver Gabrielle Alison returned $466,860 worth of shares to the company (23,343 units at $20.00), closing all direct ownership in the company

    3/3/23 9:27:04 AM ET
    $OPNT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OPNT alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
    X
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    Silver Gabrielle Alison

    (Last) (First) (Middle)
    C/O OPIANT PHARMACEUTICALS, INC.
    233 WILSHIRE BLVD, SUITE 400

    (Street)
    SANTA MONICA CA 90401

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    OPIANT PHARMACEUTICALS, INC. [ OPNT ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    03/02/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 03/02/2023 D(1) 21,343 D $20 2,000 D
    Common Stock 03/02/2023 D(2) 2,000 D $20 0 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy) $15.56 03/02/2023 D(3) 2,500 06/13/2019 06/12/2028 Common Stock 2,500 $0 0 D
    Stock Option (right to buy) $12.75 03/02/2023 D(3) 2,500 06/12/2020 06/11/2029 Common Stock 2,500 $0 0 D
    Common Stock $8.79 03/02/2023 D(3) 2,500 06/15/2021 06/15/2030 Common Stock 2,500 $0 0 D
    Stock Option (right to buy) $13.3 03/02/2023 D(3) 2,500 06/15/2022 06/14/2031 Common Stock 2,500 $0 0 D
    Explanation of Responses:
    1. Disposed of pursuant to that certain Agreement and Plan of Merger between the Issuer, Indivior Inc., and Olive Acquisition Subsidiary, Inc., dated as of November 13, 2022 (the "Merger Agreement"), in exchange for a cash payment of $20.00 per share without interest thereon (the "Merger Consideration").
    2. Disposed of pursuant to the Merger Agreement in exchange the Merger Consideration. The number of shares disposed of reflects 2,000 shares of Common Stock upon the acceleration of vesting of restricted stock units in accordance with the Merger Agreement.
    3. The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares.
    Remarks:
    /s/ Dr. Gabrielle A. Silver 03/03/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $OPNT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OPNT

    DatePrice TargetRatingAnalyst
    12/9/2021$42.00Outperform
    Oppenheimer
    More analyst ratings

    $OPNT
    SEC Filings

    See more
    • SEC Form 15-12G filed by Opiant Pharmaceuticals Inc.

      15-12G - OPIANT PHARMACEUTICALS, INC. (0001385508) (Filer)

      3/13/23 6:15:56 AM ET
      $OPNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Opiant Pharmaceuticals Inc.

      EFFECT - OPIANT PHARMACEUTICALS, INC. (0001385508) (Filer)

      3/10/23 12:15:14 AM ET
      $OPNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Opiant Pharmaceuticals Inc.

      EFFECT - OPIANT PHARMACEUTICALS, INC. (0001385508) (Filer)

      3/10/23 12:15:06 AM ET
      $OPNT
      Biotechnology: Pharmaceutical Preparations
      Health Care